Philippe Dro brings entrepreneurial expertise and biotech, medtech and pharma industry experience
Successful serial entrepreneur with track record of growing companies, notably for Themis and GlycoVaxyn
Joins at a key juncture in Scenic Biotech’s strategic growth, building its pipeline of genetic modifier drug candidates
AMSTERDAM, The Netherlands, February 02, 2021 / B3C newswire / Scenic Biotech BV (“Scenic”), a pioneer in the discovery of genetic modifiers to enable the development of disease modifying therapeutics for rare genetic disorders and other devastating illnesses, today announced that it has appointed Dr. Philippe Dro as its independent Chairman. A highly experienced entrepreneur, he replaces Dr. Ulrich Grau who retires from the Board of Directors.
Doğan Holding yeni bir halka arza hazırlanıyor ogunhaber.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ogunhaber.com Daily Mail and Mail on Sunday newspapers.
Doğan Holding, Galata Wind Enerji yi halka arz edecek dunya.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dunya.com Daily Mail and Mail on Sunday newspapers.
U.S.$2.50
(1) The Consent Payment (as defined in the Consent Solicitation Statement) for the Consent Solicitations with respect to each series of Notes is an amount, per U.S.$1,000 aggregate principal amount of the applicable Series of Notes for which a Holder thereof has delivered valid and unrevoked Consents to the applicable Proposed Amendments (on or prior to the applicable Expiration Date). No accrued interest will be paid in connection with the Consent Solicitations. Holders who validly deliver (and do not validly revoke) their Consents on or prior to the applicable Expiration Date will receive the Consent Payment, subject to the terms and conditions set forth in the Consent Solicitation Statement.